Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Aprea Logo
Aprea Growth Score
81
CB Rank
51869
Heat Score
68
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Founded
obfuscation
PublicPost-IPO Equity Stockholm, Stockholms Lan, Sweden1-10 aprea.com/
Biotechnology
Health Care
Medical
Personal Health
Pharmaceutical
Overview

Aprea
Total Funding
obfuscation
Growth Score
81
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score81
-15 pts
in past quarter
Heat Score 68
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Aprea

CB Rank
51869
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Founded
obfuscation
PublicPost-IPO Equity Stockholm, Stockholms Lan, Sweden1-10 aprea.com/
Biotechnology
Health Care
Medical
Personal Health
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Christian Schade
    Christian Schade: President and chief executive officer
    Past Role: Halda Therapeutics, Chief Executive Officer
  • Photo of Scott Coiante
    Scott Coiante: Senior Vice President & Chief Financial Officer
    Past Role: Ernst & Young, Senior Manager,Position, Biotechnology and Pharmaceutical Industries.

Details

Legal Name Aprea Therapeutics AB
Also Known As Aprea Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:APRE
Company Type For Profit
Founders  Galina Selivanova, Klas Wiman
About the Company

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development.

Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman

and Galina Selivanova.

Phone Number +460850884504
Contact Email info@aprea.com
Predictions & Insights

Growth Insight

See this Growth Insight
Aprea is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ATRN-119
A small molecule ATR inhibitor in Phase 1 development targeting solid tumors by disrupting DNA damage response pathways.
APR-1051
An orally bioavailable, selective WEE1 kinase inhibitor targeting cancers with Cyclin E overexpression, including therapy-resistant breast and ovarian cancers.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity
obfuscation
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
3
obfuscation
Soleus CapitalPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Vestal Point Capital Logo
Vestal Point Capital
—
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
—
Vestal Point Capital Logo
Vestal Point Capital
—
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
—
Vestal Point Capital Logo
Vestal Point Capital
—
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
—
Vestal Point Capital Logo
Vestal Point Capital
—
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
—
Vestal Point Capital Logo
Vestal Point Capital
—
Post-IPO Equity - Aprea Logo
Post-IPO Equity - Aprea
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 5 Contacts 3

Employee Profiles

News

News and Press

News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,584
23.56%
 in past month

IT Spend

$27.9KThis year, Aprea is projected to spend $27.9K on IT, according to Aberdeen.

Actively Used Products

15Aprea uses 15 technology products and services including HTML5, Comodo PositiveSSL Certificates, and  Gravity Forms, according to G2 Stack.

Active Website Tech Count

20Aprea is actively using 20 technologies for its website, according to BuiltWith. These include HSTS, nginx, and  jQuery CDN.

Total IP

9The intellectual property of Aprea includes 9 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
Atrin Pharmaceuticals Logo
Atrin PharmaceuticalsSubsidiary
Frequently Asked Questions

Where is Aprea's headquarters? Aprea is located in Stockholm, Stockholms Lan, Sweden.Who invested in Aprea? Aprea has 20 investors including Vestal Point Capital and  Soleus Capital.When was the last funding round for Aprea? Aprea closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Aprea's competitors? Alternatives and possible competitors to Aprea may include Tango Therapeutics, Nuvalent, and  Avenzo Therapeutics.How much funding has Aprea raised to date? Aprea has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|